Weiss Ratings Reiterates "Sell (D)" Rating for Chemours (NYSE:CC)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D)" rating for Chemours, indicating continued bearish sentiment towards the company's stock.
• Despite the negative rating from Weiss, five analysts currently rate Chemours as a "Buy," with a consensus target price set at $18.13.
• Chemours recently reported earnings that beat estimates, showing a 5% increase in revenue year-over-year, while the CEO has increased her stake in the company.

Chemours (NYSE:CC - Get Free Report)'s stock had its "sell (d)" rating reaffirmed by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Several other equities analysts have also recently weighed in on CC. Zacks Research raised shares of Chemours from a "strong sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Mizuho lifted their price target on shares of Chemours from $16.00 to $19.00 and gave the stock an "outperform" rating in a report on Tuesday, September 23rd. Truist Financial lifted their price objective on shares of Chemours from $18.00 to $21.00 and gave the company a "buy" rating in a research note on Tuesday, September 16th. UBS Group lifted their price objective on shares of Chemours from $17.00 to $21.00 and gave the company a "buy" rating in a research note on Monday. Finally, Royal Bank Of Canada lifted their price objective on shares of Chemours from $14.00 to $15.00 and gave the company an "outperform" rating in a research note on Thursday, July 3rd. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Chemours has a consensus rating of "Hold" and a consensus target price of $18.13.

Chemours Stock Performance

NYSE CC traded down $0.04 during trading on Wednesday, reaching $15.05. 2,493,046 shares of the company's stock were exchanged, compared to its average volume of 2,896,155. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83. The business has a 50 day moving average price of $15.10 and a 200-day moving average price of $13.02. The stock has a market capitalization of $2.25 billion, a P/E ratio of -5.38 and a beta of 1.65. Chemours has a fifty-two week low of $9.13 and a fifty-two week high of $22.38.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.12. The firm had revenue of $1.62 billion for the quarter, compared to the consensus estimate of $1.57 billion. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The company's revenue was up 5.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.38 EPS. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts forecast that Chemours will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Chemours news, CEO Denise Dignam acquired 4,068 shares of the business's stock in a transaction on Friday, August 8th. The shares were acquired at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the acquisition, the chief executive officer owned 191,546 shares in the company, valued at $2,310,044.76. This trade represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.47% of the company's stock.

Institutional Investors Weigh In On Chemours

A number of institutional investors have recently made changes to their positions in CC. Millennium Management LLC grew its holdings in shares of Chemours by 60.4% during the first quarter. Millennium Management LLC now owns 4,022,782 shares of the specialty chemicals company's stock valued at $54,428,000 after buying an additional 1,515,520 shares during the last quarter. Scopia Capital Management LP increased its stake in Chemours by 71.7% in the 2nd quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company's stock worth $38,418,000 after buying an additional 1,401,539 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Chemours by 8.3% during the first quarter. Vanguard Group Inc. now owns 16,487,008 shares of the specialty chemicals company's stock valued at $223,069,000 after purchasing an additional 1,263,047 shares in the last quarter. State Street Corp grew its position in shares of Chemours by 22.7% during the second quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company's stock valued at $70,009,000 after purchasing an additional 1,131,682 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in Chemours by 41.4% in the second quarter. Geode Capital Management LLC now owns 3,484,416 shares of the specialty chemicals company's stock worth $39,901,000 after acquiring an additional 1,020,933 shares in the last quarter. Hedge funds and other institutional investors own 76.26% of the company's stock.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.